| Literature DB >> 35887692 |
Anna Polewczyk1,2, Wojciech Jacheć3, Maciej Polewczyk4,5, Dorota Szczęśniak-Stańczyk6, Andrzej Kutarski6.
Abstract
Infections involving cardiac implantable electronic devices (CIEDs) occur at different times after device-related procedures. The aim of this study was to investigate the timing of onset and factors influencing the occurrence of all types of CIED infections to identify the type of pathogen and to examine the long-term survival of patients with all types of CIED infections. We performed a post hoc analysis of the clinical data from 3344 patients who underwent transvenous lead extraction (TLE) at a single high-volume center between 2006 and 2020, including a group of 890 patients with CIED infections. The occurrence of pocket infection (PI), lead-related infective endocarditis (LRIE) and PI coexisting with LRIE (PI + LRIE) was assessed at the following time intervals: 0-12 months, 13-36 months and > 36 months since last CIED-related procedure. In the study group, there were 274 (30.79%) early infections, 266 (29.89%) delayed infections and 350 (39.32%) late infections. Pocket infection was the most common early complication (97; 39.43%), while LRIE was predominant over 36 months from the last CIED procedure (172; 54.09%). The most common early infections were PIs that were associated with the preceding CIED-related procedure. Late LRIE was most likely to occur in patients with intracardiac lead abrasion. The probability of early versus late LRIE was higher in patients with CoNS cultures. The timing of infection onset irrespective of its type does not affect long-term survival after transvenous lead extraction. The majority of infectious complications (69%) occur more than 12 months after the last CIED-related procedure. Early infections are probably associated with pocket contamination during CIED-related procedure, while delayed and late systemic infections are related to other lead-dependent factors (especially to intracardiac lead abrasion). Time to LRIE onset is associated with pathogen type. The timing of symptom onset does not affect long-term survival after TLE.Entities:
Keywords: cardiac implantable electronic device related infection; lead-related infective endocarditis; pathogens; pocket infection; time to infection onset
Year: 2022 PMID: 35887692 PMCID: PMC9319565 DOI: 10.3390/jcm11143929
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.964
Prevalence of CIED infections at each time interval after a CIED-related procedure for noninfectious indications.
| Number of Cases | 0–12 Months | 13–36 Months | >36 Months | |
|---|---|---|---|---|
| Infection (all); n (%) | 890 | 274 | 266 | 350 |
| Isolated pocket infection (PI); n (%) | 246 | 97 | 70 | 79 |
| Pocket infection with concomitant lead-related infective endocarditis (PI + LRIE); n (%) | 326 | 117 | 110 | 99 |
| Isolated lead-related infective endocarditis (LRIE); n (%) | 318 | 60 | 86 | 172 |
CIED—cardiac implantable electronic device, LRIE—lead related infective endocarditis, PI—pocket infection.
Clinical and procedural findings depending on type of infection and temporal onset related to last CIED procedure for noninfectious indications.
| Early (E) | Delayed | Late | ANOVA | Early | Delayed | Late | ANOVA | Early | Delayed | Late | ANOVA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 11 12 13 | 2 6 10 | 3 7 11 | 4 8 12 | 5 9 13 | |||
| All | PI | 0–12 month | 13–36 month | >36 |
| PI | 0–12 month | 13–36 month | >36 |
| LRIE | 0–12 | 13–36 | >36 month |
|
|
|
|
| |
| Time to TLE since last CIED procedure [months], (mean ± SD) | 35.73 | 31.46 | 5.84 | 23.94 ±7.94 | 69.59 | 28.81 | 5.54 | 22.64 | 63.17 | <0.001 | 46.13 | 6.53 | 23.24 | 71.38 | <0.001 | <0.001 | 0.200 | 0.447 | 0.062 | |
| Patient characteristics | ||||||||||||||||||||
| Number of patients; n (%) | 890 | 246 | 97 (39.43) | 70 E (28.46) | 79 (32.11) | 326 | 117 | 110 | 99 | 318 | 60 | 86 E | 172 | |||||||
| Patient age during last procedure before TLE [years] | 65.20 | 67.19 | 68.88 | 66.64 | 65.61 | 0.079 | 66.66 | 66.81 | 66.59 | 66.57 | 0.665 | 62.18 | 63.76 3 | 64.53 | 60.46 | 0.052 | <0.001 | 0.061 | 0.278 | 0.004 |
| Female patient; n (%) | 275 | 72 (29.27) | 37 (38.14) | 11 E | 24 (30.38) | 0.007 | 99 | 41 | 32 | 26 | 0.354 | 104 | 19 | 29 4 | 56 | 0.965 | 0.426 | 0.786 | 0.044 | 0.518 |
| NYHA [class]; | 2 | 2 | 2 | 2 | 2 | 0.992 | 2 | 2 | 2 | 2 | 0.991 | 2 2 66 | 2 | 2 | 2 5 99 | 0.288 | 0.002 | 0.689 | 0.491 | 0.006 |
| LVEF [%]; (mean±SD) | 47.92 | 48.57 | 48.49 | 46.19 | 51.0 D | 0.079 | 47.72 ±14.50 | 48.34 | 46.09 ±14.55 | 48.79 | 0.355 | 47.64 | 47.72 | 45.18 | 48.68 | 0.270 | 0.626 | 0.939 | 0.958 | 0.543 |
| AF permanent; n (%) | 234 | 77 (31.30) | 28 (28.87) | 23 (32.86) | 26 (32.91) | 0.803 | 77 (23.62) | 29 (24.79) | 22 (20.00) | 26 | 0.531 | 80 | 12 | 20 | 48 | 0.428 | 0.107 | 0.461 | 0.114 | 0.502 |
| Diabetes (any) n (%) | 204 | 43 (17.48) | 18 (18.56) | 9 | 16 (20.25) | 0.465 | 74 | 25 | 28 | 21 | 0.699 | 87 22 | 19 (31.67) | 25 4 | 43 | 0.559 | 0.013 | 0.161 | 0.039 | 0.561 |
| Creatinine level [mg / dl]; (mean±SD) | 1.38 | 1.24 | 1.26 | 1.33 | 1.13 | 0.371 | 1.29 | 1.28 | 1.34 | 1.25 | 0.166 | 1.59 222 | 1.70 33 7 ±1.37 | 1.51 8 | 1.59 555 999 | 0.416 | <0.001 | 0.020 | 0.151 | 0.001 |
| System and history of pacing | ||||||||||||||||||||
| HV lead presence before TLE n (%) | 278 | 74 (30.08) | 32 (32.99) | 28 (40.00) | 14 EEE DDD (17.72) | 0.009 | 98 | 38 | 34 | 26 | 0.595 | 106 | 25 | 35 E | 46 D E | 0.026 | 0.714 | 0.387 | 0.606 | 0.595 |
| CS lead presence before TLE n (%) | 176 | 36 (14.63) | 17 (17.53) | 10 (14.29) | 9 | 0.518 | 58 | 31 | 15 E (13.64) | 12 E | 0.009 | 82 22 | 20 3
| 23 | 39 | 0.261 | 0.002 | 0.047 | 0.046 | 0.019 |
| Number of leads in the heart before TLE (mean ± SD) | 2.08 | 1.97 | 2.12 | 1.87 E | 1.86 E | 0.026 | 2.16 2 | 2.37 | 2.15 4 | 1.94 EEE L | <0.001 | 2.08 | 2.28 | 2.09 | 2.01 | 0.261 | 0.018 | 0.107 | 0.043 | 0.333 |
| Presence of abandoned leads before TLE n (%) | 123 | 26 (10.57) | 15 (15.64) | 5 | 6 | 0.132 | 56 | 32 | 16 E (14.55) | 8 E | <0.001 | 41 | 9 | 10 | 22 | 0.835 | 0.070 | 0.035 | 0.428 | 0.291 |
| Number of previous CIED-related procedures | 2 | 2 | 2 | 2 EE | 2 EE | 0.015 | 2 | 2 | 2 | 1 EEE | <0.001 | 1 2 66 | 2 333 | 2 | 1 E | 0.012 | 0.004 | 0.002 | 0.712 | 0.994 |
| Dwell time of the oldest lead per patient during TLE [months] (mean ±SD) | 91.64 | 92.39 | 89.59 | 72.23 | 113.7 DDD | <0.001 | 90.45 | 97.69 | 81.52 | 91.82 D | 0.034 | 92.29 | 67.33 3 77 | 85.62 | 104.3 | <0.001 | 0.967 | 0.016 | 0.758 | 0.238 |
| Dwell time of the oldest lead per patient during last procedure before TLE [months] (mean ±SD) | 55.40 | 57.84 | 79.97 | 48.84 EEE ±70.28 | 38.39 EEE | <0.001 | 62.28 | 91.47 | 57.83 | 33.00 EEE | <0.001 | 46.35 | 61.48 77 | 61.19 | 33.52 | <0.001 | 0.003 | 0.167 | 0.589 | 0.632 |
| History of early CIED intervention n (%) | 44 | 14 | 8 | 4 | 2 | 0.267 | 17 | 11 | 3 | 3 | 0.040 | 13 | 3 | 7 | 3 | 0.047 | 0.682 | 0.593 | 0.210 | 0.800 |
| Large lead loop presence in X-Ray before TLE n (%) | 46 | 8 | 3 | 1 | 4 | 0.457 | 14 | 5 | 6 | 3 | 0.690 | 24 2 | 3 | 5 | 16 | 0.431 | 0.010 | 0.568 | 0.314 | 0.006 |
| Leads on the both side of the chest n (%) | 28 | 4 | 2 | 1 | 1 | 0.907 | 9 | 4 | 4 | 1 | 0.443 | 15 | 4 | 3 | 8 | 0.672 | 0.093 | 0.323 | 0.670 | 0.133 |
| Lead abrasion; n (%) | 225 | 56 | 22 | 19 | 15 | 0.614 | 66 | 31 | 14 4 (12.73) | 21 | 0.041 | 113 22 666 | 21 | 29 888 | 63 55 9 | 0.840 | <0.001 | 0.147 | 0.002 | 0.001 |
| The type of last procedure before TLE | ||||||||||||||||||||
| Primary system implantation; n (%) | 404 | 100 (40.65) | 16 (16.49) | 36 EEE | 48 EEE (60.76) | <0.001 | 133 (40.80) | 17 | 55 EEE (50.00) | 61 EEE (61.62) | <0.001 | 171 22 66 (53.37) | 21 7 | 38 | 112 EEE DD
| <0.001 | <0.001 | 0.003 | 0.712 | 0.893 |
| Unit replacement; n (%) | 307 | 102 (41.46) | 58 (59.79) | 21 EEE (30.00) | 23 EEE (29.11) | <0.001 | 124 (38.04) | 61 | 38 EE (34.55) | 25 EE | 0.002 | 81 222 666 (25.47) | 23 3 | 25 | 33 EE | 0.009 | <0.001 | 0.030 | 0.645 | 0.381 |
| Up-grading of the system; n (%) | 57 | 16 | 7 | 7 | 2 | 0.172 | 20 | 8 | 7 | 5 | 0.856 | 21 | 4 | 11 | 6 D | 0.018 | 0.952 | 0.990 | 0.281 | 0.686 |
| Any CIED-related procedure (excluding primary system implantation); n (%) | 486 | 146 | 81 | 34 EEE | 31 EEE | <0.001 | 193 | 100 | 55 EEE | 38 EEE | <0.001 | 147 22 66 | 39 3 7 | 48 | 60 EEE DD | <0.001 | <0.001 | <0.001 | 0.809 | 0.893 |
Abbreviations: AF—atrial fibrillation, BMI—body mass index, CIED—cardiac implantable electronic device, CRT—cardiac resynchronization therapy, CS—coronary sinus, ICD—implantable cardioverter-defibrillator, HV—high voltage (lead), LVEF—left ventricular ejection fraction, NYHA—New York Heart Association, TLE—transvenous lead extraction. E—p < 0.05, EE—p < 0.01, EEE—p < 0.001 (E—compared to early infection, D—compared to delayed infection, L—compared to late infection within the groups: PI, PI + LRIE, LRIE). N—p < 0.05, NN—p < 0.01, NNN—p < 0.001 (compared to the data from column N). E—early, D—delayed, L—late infectious complications.
Figure 1Prevalence of CIED infections at each time interval after a CIED-related procedure for noninfectious indications.
Distribution of culture pathogens depending on type of infection and temporal onset related to last CIED procedure for noninfectious indications.
| Early | Delayed (D) | Late | ANOVA 3–5 | Early | Delayed | Late | ANOVA | Early | Delayed | Late | ANOVA | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | (11 12 13) | (2 6 10) | (3 7 11) | (4 8 12) | (5 9 13) | |||
| All pts | PI | 0–12 month. | 13–36 month | >36 month |
| PI | 0–12 | 13–36 | >36 |
| LRIE | 0–12 | 13–36 | >36 |
|
|
|
|
| |
| Number of patients (n, %) | 890 | 246 | 97 (39.43) | 70 | 79 (32.1) | 326 | 117 | 110 | 99 | 318 | 60 | 86 | 172 | |||||||
| CoNS; n (%) | 40 | 16 | 6 | 8 | 2 | 0.890 | 13 | 5 | 5 | 3 | 0.839 | 11 | 4 | 5 | 2 | 0.050 | 0.669 | 0.747 | 0.190 | 0.669 |
| Staph epidermidis; n (%) | 183 | 39 | 12 | 14 | 13 | 0.407 | 82 | 33 E 33 | 35 | 14 E DD | 0.009 | 62 | 12 | 14 D 8 | 36 | 0.670 | 0.450 | 0.018 | 0.034 | 0.449 |
| Staph aureus; n (%) | 102 | 20 | 11 | 4 | 5 | 0.330 | 54 22 | 20 | 16 | 18 E 5 | 0.766 | 28 66 | 8 | 7 | 13 L 99 | 0.386 | 0.012 | 0.476 | 0.928 | 0.012 |
| Staph—other; n (%) | 11 | 6 | 4 | 2 | 0 | 0.205 | 5 | 2 | 1 | 2 | 0.794 | 0 | 0 | 0 | 0 | 1.000 | 0.154 | 0.207 | 0.241 | 0.154 |
| STI n (%) | 60 | 10 | 2 | 4 | 4 | 0.431 | 22 | 4 | 11 | 7 | 0.141 | 28 | 5 | 9 | 14 | 0.817 | 0.669 | 0.138 | 0.512 | 0.669 |
| Streptococcus; n (%) | 3 | 0 | 0 | 0 | 0 | 1.000 | 1 | 0 | 1 | 0 | 0.375 | 2 | 0 | 0 | 2 | 0.427 | 0.514 | 1.00 | 0.497 | 0.514 |
| Other bacteria; n (%) | 64 | 10 | 6 | 3 | 1 | 0.259 | 23 | 10 | 5 | 8 | 0.448 | 31 | 6 | 9 | 16 | 0.955 | 0.077 | 0.670 | 0.155 | 0.077 |
| Culture negative; n (%) | 243 | 88 | 37 | 23 | 28 | 0.780 | 70 | 24 EE 33 | 18 E 4 | 28 | 0.108 | 85 | 15 | 28 D 88 | 42 | 0.358 | 0.137 | 0.014 | 0.010 | 0.137 |
| Lack of culture result; n (%) | 184 | 57 | 19 | 12 | 26 | 0.043 | 56 | 19 | 18 | 19 | 0.817 | 71 | 10 | 14 | 47 | 0.068 | 0.340 | 0.799 | 0.962 | 0.340 |
Abbreviations: CoNS—coagulase-negative Staphylococci, LRIE—lead-related infective endocarditis, PI—pocket infection, STI—Staphylococcus auricularis. E—p < 0.05, EE—p < 0.01 (E—compared to early infection, D—compared to delayed infection, L—compared to late infection within the groups: PI, PI + LRIE, LRIE). N—p < 0.05, NN—p < 0.01 (compared to the data from column N). E—early, D—delayed, L—late infectious complications.
Multivariate Cox regression analysis of risk factors of occurrence of different types of CIED-related infections in particular time intervals.
| Multivariate Cox Regression Analysis | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Parameters | 12 Months Follow-Up | 36 Months Follow-Up | Over 36 Months Follow-Up | ||||||
| HR | 95% CI |
| HR | 95% CI |
| HR | 95% CI |
| |
|
| |||||||||
|
|
|
| |||||||
| Patient’s age during last procedure before TLE (years) | 1.035 | 1.015–1.055 | 0.001 | 1.028 | 1.006–1.051 | 0.013 | 1.042 | 1.020–1.066 | <0.001 |
| Sex (% of female patients) (%) | 1.008 | 0.647–1.571 | 0.972 | 0.295 | 0.151–0.574 | 0.000 | 0.468 | 0.284–0.769 | 0.003 |
| AF permanent | 1.287 | 0.806–2.054 | 0.291 | 1.529 | 0.914–2.557 | 0.106 | 1.016 | 0.625–1.649 | 0.950 |
| Device type—CRT-D | 1.130 | 0.467–2.734 | 0.787 | 1.174 | 0.431–3.193 | 0.754 | 0.631 | 0.135–2.954 | 0.559 |
| Number of leads in the system before TLE | 1.054 | 0.716–1.552 | 0.788 | 0.922 | 0.599–1.417 | 0.710 | 0.948 | 0.618–1.453 | 0.806 |
| HV lead presence before TLE | 0.898 | 0.505–1.595 | 0.713 | 1.076 | 0.589–1.967 | 0.811 | 1.162 | 0.593–2.276 | 0.663 |
| Early CIED intervention in history | 1.210 | 0.570–2.567 | 0.619 | 1.129 | 0.343–3.721 | 0.841 | 1.069 | 0.260–4.396 | 0.926 |
| Dwell time of the oldest lead in the patient before TLE | 0.993 | 0.989–0.996 | 0.000 | 0.986 | 0.980–0.991 | 0.000 | 0.994 | 0.990–0.998 | 0.002 |
| Any CIED-related procedure | 7.735 | 5.507–10.865 | 0.000 | 4.294 | 2.837–6.501 | 0.000 | 3.863 | 2.513–5.936 | <0.001 |
|
| |||||||||
|
|
|
| |||||||
| Patient’s age during last procedure before TLE (years) | 1.018 | 1.001–1.036 | 0.043 | 1.028 | 1.010–1.047 | 0.002 | 1.048 | 1.027–1.071 | <0.001 |
| Sex (% of female patients) (%) | 0.862 | 0.569–1.304 | 0.481 | 0.593 | 0.383–0.919 | 0.019 | 0.452 | 0.280–0.728 | 0.001 |
| LVEF (%) | 1.410 | 0.806–2.469 | 0.229 | 1.304 | 0.699–2.433 | 0.403 | 1.325 | 0.688–2.554 | 0.400 |
| Diabetes (any) | 1.007 | 0.632–1.605 | 0.977 | 1.369 | 0.874–2.144 | 0.170 | 1.024 | 0.622–1.686 | 0.926 |
| Creatinine level (mg%) | 1.262 | 1.026–1.552 | 0.028 | 1.233 | 1.035–1.468 | 0.019 | 1.124 | 0.881–1.434 | 0.348 |
| Long-term anticoagulation therapy | 0.696 | 0.421–1.152 | 0.159 | 0.484 | 0.280–0.835 | 0.009 | 0.514 | 0.285–0.929 | 0.027 |
| Number of leads in the system before TLE | 1.414 | 0.946–2.113 | 0.091 | 1.655 | 1.083–2.532 | 0.020 | 1.109 | 0.701–1.756 | 0.658 |
| Presence of abandoned lead before TLE | 3.216 | 1.886–5.486 | 0.000 | 2.294 | 1.164–4.519 | 0.016 | 3.183 | 1.342- 7.548 | 0.009 |
| HV lead presence before TLE | 0.812 | 0.509–1.295 | 0.381 | 0.916 | 0.577–1.453 | 0.709 | 1.099 | 0.644–1.876 | 0.729 |
| CS lead presence before TLE | 0.951 | 0.512–1.769 | 0.875 | 0.433 | 0.207–0.907 | 0.026 | 0.819 | 0.375–1.787 | 0.616 |
| Early CIED intervention in history | 1.447 | 0.732–2.859 | 0.288 | 0.653 | 0.202–2.107 | 0.476 | 0.936 | 0.281–3.123 | 0.915 |
| Upgrading or additional lead implantation | 1.346 | 0.806–2.245 | 0.256 | 1.701 | 0.930–3.110 | 0.084 | 0.265 | 0.091–0.765 | 0.014 |
| Dwell time of the oldest lead before TLE | 0.994 | 0.991–0.998 | 0.001 | 0.989 | 0.985–0.993 | 0.000 | 0.985 | 0.980–0.991 | <0.001 |
| Any CIED-related procedure | 8.388 | 6.070–11.591 | 0.000 | 4.619 | 3.271–6.523 | 0.000 | 4.276 | 2.851–6.414 | <0.001 |
|
| |||||||||
|
|
|
| |||||||
| Patient’s age during last procedure before TLE (years) | 1.014 | 0.988–1.041 | 0.289 | 1.029 | 1.008–1.051 | 0.007 | 1.004 | 0.989–1.018 | 0.622 |
| Female gender | 0.896 | 0.481–1.669 | 0.730 | 0.901 | 0.542–1.497 | 0.687 | 0.666 | 0.466–0.954 | 0.027 |
| NYHA I-IV | 1.050 | 0.652–1.693 | 0.840 | 0.857 | 0.565–1.300 | 0.467 | 1.490 | 1.123–1.978 | 0.006 |
| LVEF | 1.015 | 0.990–1.040 | 0.241 | 0.988 | 0.970–1.007 | 0.228 | 1.008 | 0.995–1.021 | 0.230 |
| Diabetes (any) | 1.806 | 0.986–3.307 | 0.056 | 1.675 | 1.016–2.761 | 0.043 | 1.296 | 0.886–1.896 | 0.181 |
| Creatinine level (mg%) | 1.244 | 1.065–1.452 | 0.006 | 1.164 | 0.986–1.374 | 0.073 | 1.270 | 1.137–1.418 | 0.000 |
| Long-term antiplatelet therapy | 0.746 | 0.412–1.351 | 0.334 | 0.856 | 0.528–1.387 | 0.527 | 0.966 | 0.680–1.370 | 0.844 |
| Number of leads in the system | 1.379 | 0.823–2.312 | 0.222 | 1.061 | 0.697–1.613 | 0.783 | 0.741 | 0.538–1.019 | 0.065 |
| HV lead presence before TLE | 1.187 | 0.588–2.397 | 0.633 | 1.474 | 0.839–2.589 | 0.177 | 1.405 | 0.911–2.167 | 0.124 |
| CS lead presence before TLE | 1.505 | 0.691–3.281 | 0.304 | 1.219 | 0.641–2.321 | 0.546 | 2.322 | 1.471–3.664 | <0.001 |
| Lead implanted before age of 20 | 3.466 | 0.635–18.923 | 0.151 | 6.105 | 1.563–23.837 | 0.009 | 0.658 | 0.199–2.170 | 0.491 |
| Presence of abandoned lead before TLE | 1.458 | 0.536–3.970 | 0.460 | 1.360 | 0.610–3.030 | 0.452 | 2.210 | 1.213–4.029 | 0.010 |
| Abrasion of the lead | 2.603 | 1.371–4.943 | 0.003 | 2.402 | 1.428–4.041 | 0.001 | 2.610 | 1.792–3.801 | <0.001 |
| Leads on both sides of the chest before TLE | 3.752 | 1.036–13.588 | 0.044 | 1.923 | 0.533–6.945 | 0.318 | 1.387 | 0.538–3.578 | 0.499 |
| Dwell time of the oldest lead before TLE | 0.982 | 0.976–0.988 | 0.000 | 0.987 | 0.982–0.992 | 0.000 | 0.978 | 0.973–0.983 | <0.001 |
| Any CIED-related procedure | 5.733 | 3.662–8.975 | 0.000 | 5.497 | 3.768–8.019 | 0.000 | 5.230 | 3.890–7.030 | <0.001 |
Abbreviations: AF—atrial fibrillation, CIED—cardiac implantable electronic device, CRT—cardiac resynchronization therapy, CS—coronary sinus, HV—high voltage, LRIE—lead-related infective endocarditis, PI—pocket infection, LVEF—left ventricular ejection fraction, NYHA—New York Heart Association, TLE—transvenous lead extraction.
Clinical, procedural, bacteriological and CIED-related factors affecting onset (<12 months or >36 months) of infections after revision procedure. The results of univariable and multivariable linear regression analysis.
| Infectious Complications (All) | |||||||
|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | ||||||
| OR | 95% CI |
| OR | 95% CI |
| ||
| E | Patient age during the last procedure before TLE (one year) | 1.018 | 1.007–1.031 | 0.002 | 1.024 | 1.008–1.038 | 0.002 |
| L | NYHA (one class) | 1.269 | 1.012–1.591 | 0.039 | 1.654 | 1.213–2.256 | <0.001 |
| E | BMI (one unit) | 1.043 | 1.003–1.082 | 0.033 | 1.053 | 1.004–1.103 | 0.032 |
| E | CRT-D (yes/no) | 3.040 | 1.718–5.376 | <0.001 | 1.451 | 0.545–3.861 | 0.456 |
| E | Number of leads in the system before TLE (by one) | 1.650 | 1.282–2.123 | <0.001 | 2.387 | 1.188–4.785 | 0.014 |
| E | Number of leads in the heart before TLE (by one) | 1.618 | 1.312–1.992 | <0.001 | 0.741 | 0.398–1.377 | 0.343 |
| E | Abandoned leads (yes/no) | 2.169 | 1.376–3.425 | <0.001 | 1.524 | 0.596–3.891 | 0.378 |
| E | HV lead before TLE (yes/no) | 1.493 | 1.057–2.110 | 0.023 | 3.040 | 1.761–5.236 | <0.001 |
| E | CS lead before TLE (yes/no) | 1.613 | 1.087–2.392 | 0.017 | 0.535 | 0.270–1.059 | 0.072 |
| E | Number of previous procedures (by one) | 1.946 | 1.608–2.347 | <0.001 | 0.896 | 0.682–1.178 | 0.430 |
| E | History of early CIED intervention (yes/no) | 3.704 | 1.618–8.475 | 0.002 | 2.137 | 0.852–5.348 | 0.105 |
| E | Upgrading or additional lead implantation (yes/no) | 2.500 | 1.572–3.968 | <0.001 | 1.147 | 0.639–2.058 | 0.646 |
| E | Dwell time of oldest lead per patient during the last procedure before TLE (by one year) | 1.157 | 1.117–1.200 | <0.001 | 1.091 | 1.031–1.153 | 0.003 |
| E | Any procedure other than first system implantation (yes/no) | 6.711 | 4.651–9.709 | <0.001 | 4.016 | 2.304–6.993 | <0.001 |
| E | Presence of CoNS (yes/no) | 2.817 | 1.129–6.993 | 0.026 | 3.984 | 1.344–11.776 | 0.012 |
| Isolated pocket infection | |||||||
| E | CRT-D (yes/no) | 5.376 | 1.151–25.00 | 0.031 | 7.299 | 1.078–50.00 | 0.040 |
| E | Number of leads in the system before TLE (by one) | 1.695 | 1.012–2.833 | 0.043 | 1.271 | 0.455–3.546 | 0.645 |
| E | Number of leads in the heart before TLE (by one) | 1.650 | 1.043–2.611 | 0.031 | 0.765 | 0.316–1.848 | 0.549 |
| E | Number of previous procedures (by one) | 2.141 | 1.397–3.279 | <0.001 | 0.768 | 0.440–1.340 | 0.350 |
| E | Dwell time of oldest lead per patient during the last procedure before TLE (by one year) | 1.166 | 1.085–1.253 | <0.001 | 1.003 | 0.995–1.011 | 0.477 |
| E | Any procedure other than first system implantation (by one) | 8.547 | 4.202–17.54 | <0.001 | 10.00 | 3.378–29.41 | <0.001 |
| Pocket infection with concomitant infective endocarditis | |||||||
| E | CRT-D (yes/no) | 2.513 | 1.056–5.988 | 0.036 | 1.427 | 0.233–8.772 | 0.699 |
| E | Number of leads in the system before TLE (by one) | 1.812 | 1.160–2.833 | 0.009 | 2.538 | 0.608–10.64 | 0.199 |
| L | Number of leads in the heart before TLE (by one) | 2.092 | 1.425–3.077 | <0.001 | 0.583 | 0.162–2.101 | 0.406 |
| E | Abandoned leads (yes/no) | 4.329 | 1.880–10.00 | <0.001 | 1.815 | 0.244–13.51 | 0.558 |
| E | CS leads before TLE (yes/no) | 2.646 | 1.269–5.495 | 0.009 | 0.839 | 0.165–4.274 | 0.832 |
| E | Number of previous procedures (by one) | 3.279 | 2.174–4.926 | <0.001 | 1.506 | 0.858–2.646 | 0.152 |
| E | Upgrading or additional lead implantation (yes/no) | 6.849 | 2.532–18.52 | <0.001 | 3.745 | 0.653–21.28 | 0.136 |
| E | Upgrading or downgrading with lead abandonment (yes/no) | 5.495 | 1.550–19.61 | 0.008 | 0.479 | 0.044–5.208 | 0.543 |
| E | Dwell time of oldest lead per patient during the last procedure before TLE (by one year) | 1.203 | 1.126–1.287 | <0.001 | 1.053 | 0.955–1.160 | 0.301 |
| E | Any procedure other than first system implantation (yes/no) | 9.091 | 4.762–17.54 | 0.000 | 3.155 | 1.285–7.752 | 0.012 |
| E | Staph epidermidis (yes/no) | 2.415 | 1.200–4.854 | 0.013 | 2.326 | 0.993–5.435 | 0.051 |
| Isolated lead-related infective endocarditis | |||||||
| L | CRT-D (yes/no) | 0.366 | 0.133–1.002 | 0.049 | 1.366 | 0.305–6.117 | 0.682 |
| E | Number of leads in the system before TLE (by one) | 1.661 | 1.086–2.545 | 0.019 | 2.037 | 0.929–4.464 | 0.074 |
| L | Number of leads in the heart before TLE (by one) | 0.692 | 0.491–0.974 | 0.034 | 1.128 | 0.573–2.218 | 0.726 |
| E | HV leads before TLE (by one) | 1.908 | 1.029–3.546 | 0.039 | 3.367 | 1.401–8.130 | 0.006 |
| L | Number of previous procedures (by one) | 0.766 | 0.593–0.989 | 0.040 | 1.357 | 0.808–2.280 | 0.246 |
| E | Dwell time of oldest lead per patient during the last procedure before TLE (by one year) | 1.091 | 1.030–1.153 | 0.003 | 1.110 | 1.000–1.232 | 0.049 |
| E | Any procedure other than first system implantation (yes/no) | 3.058 | 1.653–5.650 | <0.001 | 2.475 | 0.895–6.849 | 0.079 |
| E | Presence of CoNS (yes/no) | 5.952 | 1.054–33.33 | 0.042 | 10.00 | 1.429–71.43 | 0.020 |
Abbreviations: BMI—body mass index, CIED—cardiac implantable electronic device, CoNS—coagulase-negative Staphylococci, CRT—cardiac resynchronization therapy, CS—coronary sinus, HV—high voltage, NYHA—New York Heart Association, TLE—transvenous lead extraction.
Figure 2Probability of survival depending on onset of infection: (A) All cardiac implantable device infections. (B) Isolated pocket infections. (C) Pocket infection coexisting with systemic infections. (D) Lead-related infective endocarditis. (A): Probability of survival after TLE depending on infection type p < 0.001. (B): Probability of survival after TLE due to pocket infection depending on temporal onset related to last CIED procedure p = 0.680. (C): Probability of survival after TLE due to pocket and systemic infection depending on temporal onset related to last CIED procedure p = 0.993. (D): Probability of survival after TLE due to systemic infection depending on temporal onset related to last CIED procedure p = 0.751.